Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: A multicenter cohort study

2018 ◽  
Vol 50 (1) ◽  
pp. 9-10
Author(s):  
A. Vitale ◽  
F.P. Russo ◽  
C. Sposito ◽  
A. Cucchetti ◽  
G. Levi Sandri ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cohort Study ◽  
Hepatitis C ◽  
Hepatic Resection ◽  
Direct Acting Antivirals ◽  
Multicenter Cohort Study ◽  
Hepatitis C Treatment ◽  
Pathological Characteristics ◽  
Multicenter Cohort ◽  
Direct Acting

The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study

Hepatology ◽  
2018 ◽  
Vol 67 (6) ◽  
pp. 2244-2253 ◽  
Author(s):  
Darrick K. Li ◽  
Yanjie Ren ◽  
Daniel S. Fierer ◽  
Stephanie Rutledge ◽  
Obaid S. Shaikh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Short Term ◽  
Hepatitis C Treatment ◽  
Direct Acting

scholarly journals Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e026703 ◽  
Author(s):  
Chung-Feng Huang ◽  
Ming-Lun Yeh ◽  
Ching-I Huang ◽  
Po-Cheng Liang ◽  
Yi-Hung Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Efficacy ◽  
Prospective Cohort ◽  
Direct Acting Antivirals ◽  
Svr12 Rate ◽  
Direct Acting

ObjectiveThe treatment outcome of direct-acting antivirals (DAAs) in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is controversial. The current study aimed to address the treatment efficacy and safety of DAAs in patients with curative or active HCC, compared with those of patients without HCC.DesignA prospective cohort studySettingA medical centre and two regional hospitals in TaiwanParticipantsA total of 713 Taiwanese patients (601 non-HCC, 74 curative HCC and 38 active HCC patients) who received standard-of-care DAAs were consecutively enrolled in the study.Main outcome measurementThe primary objective was to determine treatment efficacy, defined as undetectable hepatitis C virus RNA throughout 12 weeks of the post-treatment follow-up period (sustained virological response 12 [SVR12]).ResultsThe overall SVR12 rate was 96.9%. The SVR12 rate was similar between the patients with HCC and those without HCC (95.5% vs 97.2%, p=0.37). The HCC patients were divided into two groups, those with curative HCC and those with viable HCC; a substantially but not significantly lower SVR rate, 92.1% (35/38), was observed in the patients with viable HCC compared with the SVR rate, 97.3% (72/74), in those with curative HCC (p=0.33). Compared with the patients with curative HCC, the patients with viable HCC had a significantly higher proportion of serious adverse events (10.5% vs 1.0%, p=0.002), early treatment discontinuation (10.5% vs 2.8%, p=0.03) and mortality (5.3% vs 0.1%, p=0.008).ConclusionsAn equivalently high SVR rate was observed in patients with either past or active HCC compared with those without HCC. The safety concerns in the HCC patients did not compromise treatment efficacy.

Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals

2019 ◽  
Vol 31 (1) ◽  
pp. 75-79 ◽  
Author(s):  
Ashraf O. Abdelaziz ◽  
Mohamed M. Nabil ◽  
Ahmed H. Abdelmaksoud ◽  
Hend I. Shousha ◽  
Mohamed B. Hashem ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Treatment ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document